Certara downgraded by Jefferies with a new price target
$CERT
Computer Software: Prepackaged Software
Technology
Jefferies downgraded Certara from Buy to Hold and set a new price target of $17.00 from $24.50 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/8/2025 | $14.00 | Equal Weight → Overweight | Barclays |
| 2/27/2025 | $16.00 | Buy | TD Cowen |
| 9/27/2024 | $16.00 | Neutral → Buy | UBS |
| 4/10/2024 | $23.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
| 4/4/2024 | Mkt Perform | JMP Securities | |
| 2/26/2024 | $19.00 | Market Perform | Leerink Partners |
| 12/7/2023 | $17.00 | Neutral | UBS |
| 12/5/2023 | Sector Weight | KeyBanc Capital Markets |
4 - Certara, Inc. (0001827090) (Issuer)
4 - Certara, Inc. (0001827090) (Issuer)
4 - Certara, Inc. (0001827090) (Issuer)
RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the first quarter of fiscal year 2025. First Quarter Highlights: Revenue was $106.0 million, compared to $96.7 million in the first quarter of 2024, representing growth of 10%. Software revenue was $46.4 million, compared to $39.3 million in the first quarter of 2024, representing growth of 18%.Services revenue was $59.6 million, flat compared to $57.3 million in the first quarter of 2024, representing growth of 4%. Net income was $4.7 million, a $9.4 million increase compared to a net loss of $4.7 million in t
RADNOR, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: BofA Securities 2025 Healthcare ConferenceDate and Time: Tuesday, May 13 at 3:40 p.m. PT William Blair 45th Annual Growth Stock ConferenceDate and Time: Wednesday, June 4 at 12:40 p.m. CT Live webcasts for each of the conferences will be available on Certara's investor relations website at https://ir.certara.com and will be available for replay for at least 90 days thereafter. About CertaraCertara accelerates medicines using biosimulation software, technology, and
RADNOR, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the launch of its Non-Animal Navigator™ solution designed to help biopharmaceutical companies lead the transition ignited by the FDA's Roadmap to Reducing Animal Testing in Preclinical Safety Studies. The Roadmap marks a pivotal moment in drug development. Companies that act now can future-proof their portfolios, gaining competitive advantage through faster timelines, lower costs, and stronger predictive evidence. Globally, there are thousands of monoclonal antibodies and antibody-drug conjugates (ADCs) currently in the preclinical phase of devel
RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the first quarter of fiscal year 2025. First Quarter Highlights: Revenue was $106.0 million, compared to $96.7 million in the first quarter of 2024, representing growth of 10%. Software revenue was $46.4 million, compared to $39.3 million in the first quarter of 2024, representing growth of 18%.Services revenue was $59.6 million, flat compared to $57.3 million in the first quarter of 2024, representing growth of 4%. Net income was $4.7 million, a $9.4 million increase compared to a net loss of $4.7 million in t
Reiterates Full-Year 2025 GuidanceArsenal Capital Partners agrees to a one-year lock-up RADNOR, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced expected revenue and bookings for the first quarter of 2025 based upon a preliminary review of first quarter results. Additionally, the company announced that its Board of Directors has authorized a stock repurchase program under which the company may repurchase up to $100 million of its outstanding common stock. "We are pleased with our first quarter performance, driven by strong commercial execution and demand for our software and services," said
RADNOR, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the fourth quarter and full year 2024. Fourth Quarter Highlights: Revenue was $100.4 million, compared to $88.0 million in the fourth quarter of 2023, representing growth of 14%. Software revenue was $42.3 million, compared to $33.6 million in the fourth quarter of 2023, representing growth of 26%.Services revenue was $58.1 million, compared to $54.4 million in the fourth quarter of 2023, representing growth of 7%. Net income was $6.6 million, compared to a net loss of $12.5 million in the fourth quarter of 2023.Adjuste